Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, continues to pose significant global health challenges. Adequate diagnosis and management are crucial to mitigate its impact on public health.
Early diagnosis of enteric fever is pivotal in reducing morbidity and mortality. Blood culture remains the gold standard for diagnosis, with a sensitivity of 40-60% in the first week of illness. PCR-based methods are promising, but their use is limited due to high costs and requirement of specialized laboratories. Serology tests like Widal test, although widely used, have low specificity and sensitivity.
Antimicrobial therapy forms the cornerstone of enteric fever management. Fluoroquinolones were once the treatment of choice, but increasing resistance has necessitated the use of alternatives. Azithromycin and third-generation cephalosporins like ceftriaxone are now first-line treatments. Antimicrobial susceptibility testing is recommended to guide therapy.
Vaccination is a key preventive measure against enteric fever. Two vaccines are currently available: the oral live-attenuated Ty21a vaccine and the injectable Vi polysaccharide vaccine. Both vaccines are moderately effective and should be considered in endemic areas and for travelers to such regions.
Beyond clinical management, public health measures including improved sanitation, safe water supplies, and food safety are crucial in controlling enteric fever. These measures, coupled with surveillance and reporting systems, can substantially reduce the disease burden.
Enteric fever remains a significant health challenge. Effective strategies encompass prompt diagnosis, appropriate antimicrobial therapy, vaccination, and public health measures. Continued research and surveillance are essential to inform practice and policy, ultimately aiming to eradicate this preventable disease.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation